Novartis Lifts Forecast as Drugmaker Counters Covid Impact

Bookmark
(Bloomberg) -- Novartis AG’s outlook for the year has improved as the Swiss drugmaker’s new products, including a gene therapy that sells for $2.1 million, help counter disruption from Covid-19.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.